CClaimWatch
Plaintiff counsel in 3 cases

Lester Rene Hooker

Saxena White P.A.

Address of record
7777 Glades Road, Suite 300, Boca Raton, FL 33434, United Sta, 561-394-3399
Email
lhooker@saxenawhite.com
Phone
(561) 394-3399
Fax
Fax 561-394-3382

Contact details as filed with the court in the cases below.

4
Cases tracked
0 active · 4 settled
$170.3M
Plaintiff-side recovery
Disclosed settlement funds
Defense-side exposure
Resolved in settlements
4
Cases with values
of 4 tracked

Case history

Publicly tracked matters where this attorney is listed as counsel.

Plaintiff counselSettled — claims closed

Wells Fargo Securities Action Settlement

Wells Fargo allegedly made false and misleading statements about its diversity hiring initiative, the Diverse Search Requirement. The company failed to disclose that it was conducting widespread "fake" or sham interviews of diverse candidates under this policy. When The New York Times revealed this conduct on June 9, 2022, Wells Fargo shareholders suffered losses. Wells Fargo denies all allegations and admits no wrongdoing.

Settlement fund
$85M
Claim deadline
April 14, 2026
Represents
West Palm Beach Firefighters Pension Fund, Fire and Police Employees Retirement System of the City of Baltimore
Plaintiff counselSettled — claims closed

CareDx Securities Litigation Settlement

CareDx, Inc. and other defendants agreed to settle a securities class action lawsuit. The settlement resolves claims that class members were damaged by their purchases of CareDx common stock. The defendants agreed to pay $20,250,000 to settle the case.

Settlement fund
$20.3M
Claim deadline
November 12, 2025
Plaintiff counselSettled — claims closed

Snap Inc. Securities Settlement

Snap Inc. is paying $65 million to settle a class action securities lawsuit. The settlement resolves claims that purchasers and sellers of Snap Inc. securities were damaged by alleged misconduct during the class period.

Settlement fund
$65M
Claim deadline
May 6, 2026
CounselSettled — claims closed

FibroGen, Inc. Securities Litigation Settlement

FibroGen and its executives allegedly misrepresented the safety profile and Phase III trial results of its anti-anemia drug Roxadustat in filings with the FDA. Investors claim the company's stock price was artificially inflated by these false statements and declined when the truth was revealed. The defendants deny all allegations of wrongdoing.

Settlement fund
$28.5M
Claim deadline
Represents
Employees' Retirement System of the City of Baltimore, City of Philadelphia Board of Pensions and Retirement, Plymouth County Retirement Association

“Recovery” and “exposure” refer to total disclosed settlement funds in associated cases, not money personally won or lost by an attorney. Settlements generally resolve disputed allegations without a finding that either side won. Data comes from public court dockets and may be incomplete.